三元生物(301206.SZ):目前阿洛酮糖2000噸產線可產固體2000噸,液體3000噸,剩餘產能預計今年年底前完成
格隆匯7月18日丨有投資者向三元生物(301206.SZ)提問,“公司阿洛酮糖現有產能5000噸,請問,目前是否滿產?後續15000噸產能最快何時可以投產?公司有無進一步擴大阿洛酮糖產能的計劃?”
三元生物回覆稱,目前公司阿洛酮糖2000噸產線可產固體2000噸,液體3000噸,剩餘產能預計今年年底前完成,後續阿洛酮糖產能計劃根據市場情況來決定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.